跳至主要内容
临床试验/NL-OMON25723
NL-OMON25723招募中不适用

SEVRA-TRIAL Safety and efficacy of vaccination with T cell-dependent and T cell-independent primary and recall antigens in patients with rheumatoid arthritis treated with anti TNF-á antibodies (adalimumab) and anti B cell therapy (Rituximab).

Philip Remans, MD,PhD, Division of Clinical Immunology and Rheumatology, Hans Schipper, MD, PhD, Department of Internal Medicin, Theo Out, PhD, laboratory of Medical Immunology, René Lutter, PhD, Department of Experimental immunology, Ruth klaasen, MD, Division of Clinical Immunology and Rheumatology, Danielle Gerlag, MD, Division of Clinical Immunology and Rheumatology, Paul P. Tak, MD, PhD, Professor of Medicine.0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
40

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Able and willing to give written informed consent;
  • 2. A diagnosed according to the revised 1987 criteria of the American College of Rheumatology (ACR) for at least 3 months;

排除标准

  • 1. A positive PPD skin test (> 4 mm induration);
  • 2. Pregnancy;

研究者

发起方
Philip Remans, MD,PhD, Division of Clinical Immunology and Rheumatology, Hans Schipper, MD, PhD, Department of Internal Medicin, Theo Out, PhD, laboratory of Medical Immunology, René Lutter, PhD, Department of Experimental immunology, Ruth klaasen, MD, Division of Clinical Immunology and Rheumatology, Danielle Gerlag, MD, Division of Clinical Immunology and Rheumatology, Paul P. Tak, MD, PhD, Professor of Medicine.

相似试验